Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Thailand
UK
Ukraine
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds increased on 16 February 2022 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
| % of shares and voting rights (total of point A) | % of shares and voting rights through financial instruments (total of point B) | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 5.07% shares Below 5% voting rights | 0.11% shares Below 5% voting rights | 5.18% shares Below 5% voting rights | 141,134,278 shares 801,859,012 voting rights |
| Position of previous notification (if applicable) | 4.89% shares Below 5% voting rights | 0.15% shares Below 5% voting rights | 5.05% shares Below 5% voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
| Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009014377 | 7,159,012 shares Below 5% voting rights | 5.07% shares Below 5% voting rights | ||
| POINT A SUBTOTAL | ||||
Point B: Financial instruments according to SMA 9:6a:
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| Securities Lent | N/A | N/A | Physical | 161,148 shares Below 5% voting rights | 0.11% shares Below 5% voting rights |
| CFD | N/A | N/A | Cash | 3,333 shares Below 5% voting rights | 0.00% shares Below 5% voting rights |
| POINT B SUBTOTAL | 164,481 shares Below 5% voting rights | 0.11% shares Below 5% voting rights |
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
